106565-70-2

Upstream product

• 118605-55-3 (2,3,4,6-tetra-O-pivaloyl-α-D-galactopyranoside)-1-trichloroacetimidate 
• 118711-45-8 (2S,3R,4E)-2-azido-1-(galactopyranosyloxy)octadec-4-en-3-ol 
• 916159-70-1 (2S,3R)-(E)-2-azido-1-(tert-butyldiphenylsilyloxy)octadec-4-en-3-ol 
• 103348-50-1 (2S,3R,4E)-2-azido-3-benzoyloxy-4-octadecen-1-ol 
• 2021-84-3 α-galactosyl fluoride 
• 123-78-4 (2S,3R,4E)-2-amino-4-octadecene-1,3-diol 

Downstream Products

• 36271-49-5 (2S,3R,4E)-1-(β-D-galactopyranosyloxy)-2-(octadecanoylamino)-3-hydroxyoctadec-4-ene 
• 17283-91-9 (2S,3R,4E)-1-(β-D-galactopyranosyloxy)-2-(15(Z)-tetracosenoylamino)-3-hydroxyoctadec-4-ene 
• 34324-89-5 (2S,3R,4E)-1-(β-D-galactopyranosyloxy)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-ene 
• 35823-61-1 N-Acetylpsychosine 
• 41613-16-5 C₃₂H₆₁NO₈ 
• 73039-25-5 erythro-N-oleoyl-1-O-β-D-galactosyl-D-sphingosine 
• 173067-83-9 4,6-O-p-methoxybenzylidene-β-D-galactopyranosyl-(1<*>1)-(2S,3R,4E)-2-dichloroacetamido-4-octadecen-1,3-diol 
• 173067-85-1 2,3-di-O-benzoyl-β-D-galactopyranosyl-(1<*>1)-(2S,3R,4E)-3-O-benzoyl-2-dichloroacetamido-4-octadecen-1,3-diol 
• 173067-86-2 2,3,6-tri-O-benzoyl-β-D-galactopyranosyl-(1<*>1)-(2S,3R,4E)-3-O-benzoyl-2-dichloroacetamido-4-octadecen-1,3-diol 
• 173067-84-0 2,3-di-O-benzoyl-4,6-O-p-methoxybenzylidene-β-D-galactopyranosyl-(1<*>1)-(2S,3R,4E)-3-O-benzoyl-2-dichloroacetamido-4-octadecen-1,3-diol 
• 173067-87-3 2,3,6-tri-O-benzoyl-4-O-trifluoromethylsulfonyl-β-D-galactopyranosyl-(1<*>1)-(2S,3R,4E)-3-O-benzoyl-2-dichloroacetamido-4-octadecen-1,3-diol 
• 173067-88-4 S-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1<*>4)-2,3,6-tri-O-benzoyl-4-thio-β-D-glucopyranosyl-(1<*>1)-(2S,3R,4E)-3-O-benzoyl-2-dichloroacetamido-4-octadecen-1,3-diol 
• 88035-98-7 2-Hydroxy-N-[(E)-2-hydroxy-1-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxymethyl)-heptadec-3-enyl]-malonamic acid tetradecyl ester 

Relevant academic research and scientific papers

Glycosynthase mediated synthesis of psychosine

Globoid cell leukodystrophy (GCL), or Krabbe disease, is a lysosomal storage disorder characterized by a deficiency in galactosylceramidase (GALC), which hydrolyses galactosylceramide and galactosylsphingosine (psychosine). Early detection of GCL in newborns is essential for timely therapeutic intervention and could be achieved by testing infant blood samples with isotopically labeled lysosmal enzyme substrates and mass spectrometry. While isotopically labeled psychosine would be a useful tool for the early diagnosis of GCL, its synthesis is lengthy and expensive. To obviate this problem we developed a one-step chemoenzymatic synthesis of psychosine using a glycosynthase mutant of the Rhodococcus equi endogalactosylceramidase (EGALC), α-D-galactopyranosyl fluoride and sphingosine.

3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF

Disclosed is a compound of the formula (I) or (II): wherein a f are as described herein. The compounds are useful in the activation of Type II NKT cells and in treating cancer.

Synthesis and biological evaluation of antifungal activities of novel 1,2-trans glycosphingolipids

The synthesis and in-vitro biological evaluation of antifungal activities of a series of 1,2-trans glycosphingolipids (GSL) against Candida albicans, Candida parapsilosis, and Candida tropicalis were described. The preliminary study indicated that the sor

Pyridinecarboxamide or trimethoxybenzamide compounds derived from nitrogenous lipids, pharmaceutical compositions containing same which possess anti-convalsive and anti-epileptic properties

Organic amide compounds of the formula STR1 wherein R1 --CO is a residue of a carboxylic acid with the proviso that the carboxylic acid is not a natural fatty acid normally bound to nitrogen of nitrogenous lipids, R2 is a hydrogen atom, a C1-7 alkyl group, or a C4-7 cycloalkyl group, and R3-N is a residue of a nitrogenous lipid. The compounds are useful in increasing or stimulating the in vivo biological activity of in vitro biologically active carboxylic acids.